While much effort has been devoted to studying and targeting of well-recognized breast cancer drivers, including the estrogen receptor (ER), HER2 receptor, and the PI3K/AKT/mTOR pathways, many aspects of breast cancer biology, which could offer new treatment approaches, remain relatively unexplored. This evidence concerns the gene MTOR and breast carcinoma.